EMA & FDA apply a similar mindset when providing scientific advice for Live Biotherapeutic Product development

BORDEAUX & NARBONNE, France – The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) apply an aligned and complimentary mindset when advising the clinical development steps for live biotherapeutic products (LBPs), YSOPIA Bioscience and the Pharmabiotic Research Institute (PRI) have found. YSOPIA Bioscience and PRI coordinate EMA/FDA scientific advice mechanisms to […]

More